| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10345
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate |
2002-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85cb8b6348cc811ec386aab7b4c7643e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e235dfe2bfce16a662027456a0fc9c3c |
| publicationDate |
2003-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003118555-A1 |
| titleOfInvention |
Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| abstract |
The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6916918-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008213884-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008103109-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002136707-A1 |
| priorityDate |
1998-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |